Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix raises 2025 Adjusted EBITDA outlook as Q1 net income rises to $21 million

Mixed Impact 4 of 5 earnings Written later

Pediatrix Medical Group reported first-quarter 2025 net income of $20.7 million, or $0.24 per diluted share, up from $4.0 million, or $0.05, a year earlier. Net revenue fell to $458.4 million from $495.1 million, mainly due to practice dispositions, and the company raised its full-year 2025 Adjusted EBITDA outlook to $220 million to $240 million from $215 million to $235 million.

Key points

  • Q1 2025 net income of $20.7 million ($0.24 per diluted share) vs. $4.0 million ($0.05) in Q1 2024
  • Q1 2025 net revenue of $458.4 million vs. $495.1 million, reflecting practice dispositions; same-unit net revenue grew 6.2 percent
  • Q1 2025 Adjusted EBITDA of $49.2 million vs. $37.2 million; Adjusted EPS of $0.33 vs. $0.20
  • Full-year 2025 Adjusted EBITDA outlook raised to $220 million to $240 million from $215 million to $235 million

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECMay 6, 2025, 6:50 AM ET
Accession number0000950170-25-063946

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.